Cellegy Pharmaceuticals downgraded to &quot;neutral&quot;
499096
NEW YORK, December 27  - Analyst Bal Bagwat of JM Dutton downgrades Cellegy Pharmaceuticals Incorporated (ticker: CLGY) from &quot;speculative strong buy&quot; to &quot;neutral,&quot; while reducing his estimates for the company.
622700
Great news -- your stock just got downgraded!
677416
Rivals lead to lower sales of the pharmaceutical's only marketed drug.
698753
MedImmune Inc.&#39;s cancellation of trials for an arthritis and psoriasis treatment sent the company&#39;s stock lower Monday and helped drag down the entire biotechnology sector.
210977
NEW YORK (CBS.MW) -- Shares of biotechnology company Eyetech Pharmaceuticals fell in after-hours trading Friday after a key US Food and Drug Administration advisory panel withheld approval for Macugen, a new drug to treat failing eyesight in the elderly.
457614
One of the nation&#39;s leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online today by JAMA because of its relevance to
682567
Merrill Lynch downgraded Chiron (nasdaq: CHIR - news - people ) to &quot;sell&quot; from &quot;neutral&quot; after news reports indicated a flu vaccine from GlaxoSmithKline (nyse: GSK - news - people ) could be approved by the US Food and Drug Administration as early as
337352
NEW YORK -- Standard &amp; Poor's Ratings Services said yesterday it cut its credit rating on medical device maker Boston Scientific Corp., saying weaker-than-expected sales have placed pressure on the sizable debt the company took on to buy Guidant Corp. this year.
475502
The drug company posts a wider Q3 loss than a year ago.
65620
Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
621805
First Albany Capital on Wednesday raised SuperGen Inc.&#39;s (SUPG.O: Quote, Profile, Research) stock rating to &quot;buy&quot; from &quot;neutral,&quot; following its cancer-drug deal with MGI Pharma Inc.
32938
A drug being developed by Bayer AG and Onyx Pharmaceuticals shrank tumors in 9 percent of liver cancer patients in a mid-stage clinical trial, the companies said on Wednesday.
8921
SuperGen Inc. SUPG.O on Monday said  it has withdrawn an application to market its pancreatic cancer  drug in the United States, casting a cloud on the drug's future  in the world's biggest market and sending the company's shares  down as much as 16 percent.
166901
Cellegy Pharmaceuticals Inc. shares lost nearly half their value in Monday trading after the Food and Drug Administration rejected the company&#39;s ointment for treating pain from chronic anal fissure.
246773
A drug developed by Bayer AG and Onyx Pharmaceuticals shrank tumors in some liver cancer patients in a mid-stage trial and stabilized the disease, the companies said Wednesday.
550684
Sanofi-Aventis SA cut its 2006 earnings forecast Friday, warning that generic drug maker Apotex Corp. may have flooded the U.S. market with cheaper copies of the French company's blockbuster blood-thinning pill, Plavix.
309975
UCB SA announced Friday it made the final move in its transition to a pharmaceuticals-only business, unloading Surface Specialties to Cytec Industries Inc.